Skip to main content
. 2023 Nov 3;63(6):140. doi: 10.3892/ijo.2023.5588

Figure 8.

Figure 8

Schematic diagram of the role of the MEK/ERK and PI3K/AKT pathways in MDS-AML. The MEK/ERK and PI3K/AKT pathway inhibitors, U0126 and Ly294002, respectively, regulated te H3K27me3 level by mediating the levels of EZH2/JMJD3 and EZH1/UTX, thus affecting the transcription and expression of DLX5, and ultimately participating in the regulation of MDS and AML progression. MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; EZH, enhancer of zeste homolog; H3K27me3, trimethylation of H3 on lysine 27; UTX, ubiquitously transcribed tetratricopeptide repeat on chromosome X; JMJD3, demethylase Jumonji domain-containing protein-3; JMJD3, demethylase Jumonji domain-containing protein-3.